Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares traded down 8.5% during mid-day trading on Monday . The company traded as low as $11.54 and last traded at $11.72. 515,091 shares were traded during trading, an increase of 59% from the average session volume of 323,136 shares. The stock had previously closed at $12.81.

A number of research analysts have recently issued reports on the company. BidaskClub downgraded Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Tuesday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $26.00 price target on shares of Intra-Cellular Therapies in a report on Monday, April 15th. Finally, ValuEngine raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $27.00.

The firm has a market cap of $645.97 million, a PE ratio of -4.35 and a beta of 1.39. The company has a quick ratio of 9.59, a current ratio of 9.59 and a debt-to-equity ratio of 0.07.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27. As a group, equities analysts predict that Intra-Cellular Therapies Inc will post -3.99 EPS for the current fiscal year.

In other news, Director Christopher D. Alafi acquired 100,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $12.56 per share, for a total transaction of $1,256,000.00. Following the completion of the transaction, the director now owns 750,106 shares in the company, valued at $9,421,331.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.40% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its position in Intra-Cellular Therapies by 1.9% during the fourth quarter. BlackRock Inc. now owns 4,004,666 shares of the biopharmaceutical company’s stock valued at $45,614,000 after acquiring an additional 76,356 shares during the last quarter. Vanguard Group Inc. increased its position in Intra-Cellular Therapies by 1.8% during the third quarter. Vanguard Group Inc. now owns 3,943,792 shares of the biopharmaceutical company’s stock valued at $85,580,000 after acquiring an additional 69,950 shares during the last quarter. Vanguard Group Inc increased its position in Intra-Cellular Therapies by 1.8% during the third quarter. Vanguard Group Inc now owns 3,943,792 shares of the biopharmaceutical company’s stock valued at $85,580,000 after acquiring an additional 69,950 shares during the last quarter. Wasatch Advisors Inc. increased its position in Intra-Cellular Therapies by 19.0% during the first quarter. Wasatch Advisors Inc. now owns 2,361,619 shares of the biopharmaceutical company’s stock valued at $28,765,000 after acquiring an additional 377,561 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Intra-Cellular Therapies by 12.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,623,196 shares of the biopharmaceutical company’s stock valued at $19,771,000 after acquiring an additional 178,973 shares during the last quarter. Institutional investors own 69.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Intra-Cellular Therapies (ITCI) Trading Down 8.5%” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2019/05/15/intra-cellular-therapies-itci-trading-down-8-5.html.

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

See Also: Special Dividends

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.